^
Association details:
| Biomarker: | FOLR1 positive |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Elahere (mirvetuximab soravtansine-gynx) (Microtubule inhibitor, Folate receptor 1-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
Published date:
03/22/2024
Excerpt:
...the U.S. Food and Drug Administration (FDA) has granted full approval for ELAHERE® (mirvetuximab soravtansine-gynx) for the treatment of folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal adult cancer patients treated with up to three prior therapies.
Source:
Title:
MIRVETUXIMAB SORAVTANSINE AND BEVACIZUMAB IN FOLATE RECEPTOR ΑLPHA-POSITIVE OVARIAN CANCER: EFFICACY IN PATIENTS WITH AND WITHOUT PRIOR BEVACIZUMAB
Published date:
09/12/2022
Excerpt:
As part of the phase 1b/2 trial (NCT02606305), efficacy, safety, and tolerability of MIRV and bevacizumab (BEV) were evaluated in patients with recurrent FRα-positive ovarian cancer (OC) measured by immunohistochemistry (PS2+ ≥25%)....MIRV demonstrated anti-tumor activity in the entire cohort (ORR 44%, mDOR 11.8 months, mPFS 8.2 months), with ORR of 58% in BEV-naïve and 32% in prior BEV (Table 1)….MIRV and BEV demonstrated anti-tumor activity, regardless of prior BEV treatment, and should be considered in FRα-positive recurrent OC.
Trial ID:
